세계의 생체흡수성 스텐트 시장 규모 : 재료 유형별, 용도별, 최종사용자별, 지역별, 예측

Bioabsorbable Stent Market Size and Forecast

Bioabsorbable Stent Market size was valued at USD 447.17 Million in 2024 and is projected to reach USD 993.97 Million by 2032, growing at a CAGR of 10.50 % from 2026 to 2032.

Bioabsorbable stents, which are also referred to as bioresorbable vascular scaffolds (BVS), are designed to be fully absorbed by the body over time after supporting the treated blood vessel.

These innovative devices are developed to overcome the limitations of permanent metallic stents, such as late stent thrombosis and the need for long-term dual antiplatelet therapy.

Furthermore, the technology is aimed at restoring the natural function of the vessel while reducing long-term complications associated with permanent implants.

Bioabsorbable Stent Market Dynamics

The key market dynamics that are shaping the bioabsorbable stent market include:

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs): The growing global burden of cardiovascular illnesses is a key driver of the bioabsorbable stent market. According to the World Health Organization (WHO), CVDs kill around 17.9 million people each year, accounting for 32% of all global fatalities. The growing prevalence of cardiac disease is driving demand for bioabsorbable stents, which have the advantage of decreasing difficulties associated with permanent implants, making them the preferred choice for patients requiring stent-based treatments.

Advancements in Stent Technology: Technological advances in stent design and material have accelerated the use of bioabsorbable stents in the treatment of coronary artery disease. Bioabsorbable stents, created from biodegradable polymers, disintegrate naturally after serving their purpose of maintaining the artery. According to research from the United States Food and Drug Administration (FDA), bioabsorbable stents have shown substantial potential in lowering late-stage problems such as stent thrombosis, therefore improving patient outcomes and boosting wider market adoption.

Increasing Healthcare Expenditure and Accessibility: Growing investment in healthcare infrastructure and improved access to innovative medical treatments are propelling the bioabsorbable stent market. The World Bank said that worldwide healthcare spending has continuously increased, with many countries investing more in advanced cardiovascular treatment. This increase in healthcare spending, combined with attempts to provide access to cutting-edge technologies, is driving rising demand for bioabsorbable stents as an effective therapy for coronary artery disease.

Key Challenges

Clinical Performance Concerns: Questions about the long-term efficacy and safety of bioabsorbable stents are raised by some healthcare providers. Several first-generation devices have been associated with complications, which is affecting market confidence.

Regulatory Hurdles: Strict regulatory requirements are imposed for the approval of new stent technologies. Extended clinical trials and safety data are demanded by regulatory bodies before new devices are brought to market.

High Production Costs: The manufacturing of bioabsorbable stents is found to be more complex and expensive compared to traditional metallic stents. These higher costs are passed on to healthcare providers and patients, which is limiting adoption in price-sensitive markets.

Key Trends

Personalized Medicine Approach: Customized stent designs are developed to meet individual patient needs. Advanced imaging and 3D printing technologies are utilized to create patient-specific devices.

Focus on Novel Materials: Research is conducted on new bioabsorbable materials that offer improved mechanical properties and more controlled degradation rates. Composite materials that combine the benefits of both polymers and metals are explored.

Integration of Drug-Elution Capabilities: Enhanced drug-delivery systems are incorporated into bioabsorbable stents. These advancements are aimed at improving healing outcomes and reducing the risk of restenosis.

Bioabsorbable Stent Market Regional Analysis

The regional analysis of the bioabsorbable stent market:

North America:

According to Verified Market Research, North America is estimated to dominate the bioabsorbable stent market over the forecast period. Cardiovascular diseases (CVDs) remain a leading cause of death in North America, driving the demand for advanced treatment options like bioabsorbable stents. According to the American Heart Association (AHA), nearly 121.5 million American adults had some form of cardiovascular disease by 2021. This high disease burden has resulted in increased adoption of bioabsorbable stents, which offer better long-term outcomes compared to traditional metal stents by reducing the risk of late-stent thrombosis and eliminating the need for prolonged dual antiplatelet therapy.

The North American market benefits from a supportive regulatory framework that accelerates the adoption of innovative medical technologies. The U.S. Food and Drug Administration (FDA) has been increasingly approving bioabsorbable stents for coronary artery disease treatment, promoting their use in clinical settings. In recent years, the FDA has fast-tracked approvals for bioabsorbable stents under its Breakthrough Devices Program, enabling quicker market access and supporting growth in the region.

Furthermore, the aging population in North America significantly contributes to the rising demand for bioabsorbable stents. The U.S. Census Bureau reports that by 2032, all baby boomers will be over the age of 65, leading to an increase in age-related cardiovascular conditions. As older adults are more likely to require stent procedures due to coronary artery disease, the need for bioabsorbable stents, which reduce long-term complications, is expected to grow steadily in the coming years.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the market during the forecast period. The increasing prevalence of cardiovascular diseases (CVDs) in Asia-Pacific, due to lifestyle changes and aging populations, is a significant driver of the bioabsorbable stent market. According to the World Health Organization (WHO), CVDs account for over 75% of premature deaths in low- and middle-income countries, particularly in regions like Southeast Asia. This growing burden of CVDs is driving the demand for advanced treatments like bioabsorbable stents, which help improve patient outcomes by reducing long-term complications.

Governments in Asia-Pacific countries are investing in healthcare infrastructure and reforms to improve access to advanced medical technologies. For instance, India's National Health Policy and China's Healthy China 2032 initiative both emphasize improving cardiovascular care, including expanding the availability of cutting-edge stent technologies. These policies are encouraging the adoption of bioabsorbable stents as part of broader efforts to enhance cardiovascular treatment across the region.

Furthermore, the Asia-Pacific region, particularly countries like India, Thailand, and Malaysia, has seen rapid growth in medical tourism due to the availability of high-quality yet affordable healthcare. This trend includes a growing demand for advanced cardiovascular treatments such as bioabsorbable stents. According to the Medical Tourism Association, Asia-Pacific is one of the top destinations for medical tourists seeking cardiac procedures. This rise in medical tourism is contributing to the expansion of the bioabsorbable stent market in the region.

Bioabsorbable Stent Market: Segmentation Analysis

The Bioabsorbable Stent Market is segmented based on Material Type, Application, End-user, and Geography.

Bioabsorbable Stent Market, By Material Type

• Polymer-Based
• Metal-Based

Based on material type, the bioabsorbable stent market is segmented into Polymer-Based and Metal-Based stents. The polymer-based segment is estimated to dominate the bioabsorbable stent market due to its superior biocompatibility and gradual absorption in the body, reducing long-term complications associated with permanent stents. Polymer-based stents offer advantages such as flexibility and the ability to elute drugs to prevent restenosis, making them ideal for coronary artery disease treatment. Technological advancements in polymer materials have led to improved mechanical strength and controlled degradation, further driving the adoption of polymer-based stents.

Bioabsorbable Stent Market, By Application

• Coronary Artery Disease
• Peripheral Artery Disease

Based on application, the bioabsorbable stent market is segmented into Coronary Artery Disease and Peripheral Artery Disease. The coronary artery disease segment is estimated to dominate the bioabsorbable stent market due to the high prevalence of coronary artery disease (CAD) worldwide, which is one of the leading causes of death. Bioabsorbable stents offer significant advantages in the treatment of CAD by providing temporary support to arteries while reducing long-term complications such as restenosis and thrombosis. Technological advancements in bioabsorbable stents, such as drug-eluting designs, have further enhanced their effectiveness in treating CAD. While peripheral artery disease treatment also benefits from bioabsorbable stents, the large patient population suffering from CAD ensures this segment's dominance in the market.

Bioabsorbable Stent Market, By End-user

• Hospitals
• Cardiac Centers
• Others

Based on End-user, the bioabsorbable stent market is segmented into Hospitals, Cardiac Centers, and Others. The hospital segment is expected to dominate the bioabsorbable stent market due to the high volume of stent implantation procedures performed in these settings. Hospitals, equipped with advanced infrastructure and a broad range of specialized services, are the primary point of care for patients requiring coronary interventions. Additionally, hospitals have access to a wider range of bioabsorbable stent technologies and are more likely to adopt cutting-edge medical innovations.

Bioabsorbable Stent Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on geography, the bioabsorbable stent market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is estimated to dominate the bioabsorbable stent market due to several factors, including the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of innovative medical technologies. The region's strong regulatory framework, supported by the U.S. Food and Drug Administration (FDA), has accelerated the approval and clinical use of bioabsorbable stents. Additionally, North America benefits from significant investments in research and development, enabling continuous advancements in bioabsorbable stent technology. While Europe and Asia Pacific are also key markets, North America's robust healthcare system and high demand for minimally invasive procedures secure its leading position in the global market.

Key Players

• The "Bioabsorbable Stent Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Elixir Medical Corporation, Kyoto Medical Planning Co., Ltd., Arterius Limited, Reva Medical, Inc., Amaranth Medical, Inc., Meril Life Sciences Pvt. Ltd., and Lepu Medical Technology (Beijing) Co., Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Bioabsorbable Stent Market Recent Developments
• In June 2024, Abbott received FDA approval for its next-generation bioabsorbable stent, designed with improved polymer materials for better patient outcomes in treating coronary artery disease. This stent offers enhanced radial strength and a more predictable degradation profile, making it a significant advancement in bioabsorbable stent technology.
• In April 2024, Biotronik launched its Magmaris Resorbable Magnesium Scaffold in several European countries. The stent, made from magnesium alloy, provides temporary support to blood vessels while fully absorbed by the body, reducing long-term complications associated with traditional metal stents.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOABSORBABLE STENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources
• 3.5 Market attractiveness

4 GLOBAL BIOABSORBABLE STENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BIOABSORBABLE STENT MARKET, BY MATERIAL TYPE

• 5.1 Overview
• 5.2 Polymer-Based
• 5.3 Metal-Based

6 GLOBAL BIOABSORBABLE STENT MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Coronary Artery Disease
• 6.3 Peripheral Artery Disease

7 GLOBAL BIOABSORBABLE STENT MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospital
• 7.3 Cardiac Centers

8 GLOBAL BIOABSORBABLE STENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL BIOABSORBABLE STENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 ACE Matrix

10 COMPANY PROFILES

• 10.1 Biotronik
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Abbott Laboratories Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Boston Scientific Corporation
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Terumo Corporation
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Arterius Limited
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Elixir Medical Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Kyoto Medical Planning Co. Ltd
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Amaranth Medical
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Meril Life Sciences Pvt. Ltd
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Reva Medical
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 Svelte Medical Systems
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Lepu Medical Technology Co. LTD
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research